Price (delayed)
$1.4
Market cap
$176.06M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.21
Enterprise value
$96.42M
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and
There are no recent dividends present for ATOS.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.